Ribavirin(RBV) antibody/antigen (BSA/OVA/KLH conjugated hapten)

anti-Ribavirin(RBV) antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)

Target products collectionGo to Drugs of Abuse diagnostics products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-168-11. BSA-Ribavirin(RBV)
2. Anti-Ribavirin(RBV) mouse monoclonal antibody
$2709.00
GMP-SMT-168-21. OVA-Ribavirin(RBV)
2. Anti-Ribavirin(RBV) mouse monoclonal antibody
$2709.00
GMP-SMT-168-31. BSA-Ribavirin(RBV)
2. Anti-Ribavirin(RBV) human monoclonal antibody
$2709.00
GMP-SMT-168-41. OVA-Ribavirin(RBV)
2. Anti-Ribavirin(RBV) human monoclonal antibody
$2709.00
GMP-SMT-168-Ag-1BSA-Ribavirin(RBV)$756.00
GMP-SMT-168-Ag-2OVA-Ribavirin(RBV)$756.00
GMP-SMT-168-Ab-1Anti-Ribavirin(RBV) mouse monoclonal antibody$1953.00
GMP-SMT-168-Ab-2Anti-Ribavirin(RBV) human monoclonal antibody$1953.00

Size: 1mg | 10mg | 100mg



Product Description


BSA-Ribavirin(RBV)

Cat No.GMP-SMT-168-Ag-1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Ribavirin(RBV) with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-Ribavirin(RBV) had been validated with our anti-Hapten antibody Anti-Ribavirin(RBV) mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


OVA-Ribavirin(RBV)

Cat No.GMP-SMT-168-Ag-2
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates OVA-Ribavirin(RBV) with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-Ribavirin(RBV) had been validated with our anti-Hapten antibody Anti-Ribavirin(RBV) mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-Ribavirin(RBV) mouse monoclonal antibody

Cat No.GMP-SMT-168-Ab-1
Host of AntibodyMouse IgG
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)7-8
Products descriptionThe anti-Hapten antibody against hapten Ribavirin(RBV) had been validated with our hapten hapten-carrier conjugates BSA-Ribavirin(RBV) via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-Ribavirin(RBV) human monoclonal antibody

Cat No.GMP-SMT-168-Ab-2
Host of AntibodyHuman IgG1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)7-8
Products descriptionThe anti-Hapten antibody against hapten Ribavirin(RBV) had been validated with our hapten hapten-carrier conjugates BSA-Ribavirin(RBV) via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Biomarker Information


    1. Ribavirin (RBV) in In Vitro Diagnosis:

    Ribavirin (RBV) stands as a noteworthy small molecule of pronounced significance within the domain of in vitro diagnosis, particularly in the spheres of molecular diagnostics and virology. Classified as an antiviral agent, RBV has garnered substantial attention due to its demonstrated efficacy against a spectrum of RNA viruses, with a notable emphasis on its effectiveness against hepatitis C virus (HCV) and respiratory syncytial virus (RSV). Within the landscape of in vitro diagnosis, RBV plays an indispensable role as a reference substance and an elemental component in diverse diagnostic assays. These assays are meticulously designed to facilitate the precise detection and quantification of RNA viruses, and RBV assumes a pivotal role in ensuring the veracity and reliability of these diagnostic processes.

    Diagnostic Significance: RBV, within the realm of in vitro diagnosis, serves as an essential reference standard. It functions as a positive control or reference material in molecular diagnostic assays, such as polymerase chain reaction (PCR) and reverse transcription-PCR (RT-PCR). These molecular assays leverage RBV as a benchmark to rigorously validate the accuracy, sensitivity, and specificity of the tests, particularly in the context of identifying specific RNA viruses, with HCV serving as a prominent target. The inclusion of RBV within these diagnostic platforms accomplishes a dual objective: it substantiates the reliability of diagnostic systems and ensures the consistency of diagnostic results. Thus, RBV's presence in diagnostic assays is pivotal for quality control and assay validation.

    Quality Assurance and Validation: Beyond its role as a reference standard, RBV assumes a pivotal position in the arena of quality assurance within in vitro diagnostic procedures. Laboratories, clinical settings, and diagnostic facilities routinely employ RBV as an integral control element within their diagnostic protocols. This meticulous deployment of RBV is instrumental in meticulously scrutinizing the performance of diagnostic assays and systems, ultimately validating their precision and fidelity. Such validation assumes critical importance, especially within the purview of infectious disease diagnosis, where the accuracy and reliability of diagnostic outcomes are paramount for the formulation of efficacious patient management strategies.

    2. The Imperative of Measuring Ribavirin (RBV):

    The measurement of Ribavirin (RBV) levels encompasses multifaceted imperatives, each underscored by compelling and interrelated considerations:

    - Treatment Efficacy Assessment: RBV, as a pivotal constituent of antiviral therapy, particularly within the context of managing chronic HCV infections, assumes a critical role in the assessment of treatment efficacy. Quantifying RBV levels in patients undergoing antiviral treatment serves as a pivotal means to evaluate the therapeutic efficacy of specific regimens. Real-time RBV measurements empower healthcare providers to make data-driven adjustments to treatment protocols, thereby optimizing treatment outcomes and patient well-being. The ability to gauge the effectiveness of antiviral interventions through RBV measurements contributes significantly to the advancement of personalized medicine and tailored therapeutic strategies.

    - Therapeutic Drug Monitoring: Ongoing and vigilant monitoring of RBV levels in patients receiving RBV-based antiviral therapy stands as an indispensable strategy for ensuring the attainment of therapeutic concentrations. Inadequate RBV levels may culminate in suboptimal treatment efficacy, permitting viral replication or even the emergence of drug-resistant viral variants. Therefore, the routine measurement of RBV levels stands as a linchpin in sustaining the efficacy of antiviral interventions. Therapeutic drug monitoring not only helps maintain antiviral efficacy but also minimizes the potential for therapeutic complications, enabling healthcare providers to fine-tune treatment regimens based on individual patient responses.

    - Adverse Effects Mitigation: RBV therapy, while efficacious, can be associated with adverse effects, with hematological complications, particularly anemia, being a notable concern. Regular RBV level monitoring facilitates the early identification of untoward events, such as significant drops in hemoglobin levels. By detecting these complications promptly, healthcare providers can implement targeted management strategies, including RBV dose adjustments or adjunctive therapies, aimed at mitigating adverse effects while preserving treatment effectiveness. This proactive approach to adverse event management contributes significantly to patient safety and treatment adherence.

    - Scientific Inquiry and Clinical Advancements: Beyond its clinical utility, RBV measurements hold pivotal significance in the realm of scientific exploration and clinical research. Researchers and clinicians alike utilize RBV level data to unravel the intricate pharmacokinetic and pharmacodynamic profiles governing the actions of this antiviral agent. Insights gleaned from RBV-related research contribute substantially to the refinement of antiviral therapies, treatment guidelines, and patient-centric care paradigms. Additionally, RBV measurements serve as a cornerstone for the scientific investigation of drug interactions, pharmacogenomics, and the optimization of treatment protocols. This body of knowledge ultimately informs clinical practice, fostering the development of more effective and personalized therapeutic strategies for patients.

    In summation, the measurement of Ribavirin (RBV) assumes an indomitable role within the domain of in vitro diagnosis, serving as both a reference standard for diagnostic validation and an instrumental tool for optimizing antiviral therapy. Moreover, RBV measurements bear profound implications for the mitigation of adverse treatment effects and the advancement of scientific inquiry, culminating in enhanced diagnostic precision, patient care, and antiviral pharmacology. This comprehensive approach not only ensures rigorous diagnosis and treatment but also substantiates the scientific underpinnings of antiviral interventions, thereby contributing significantly to the advancement of medical science and patient well-being.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.